Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
he present art of drug discovery and design of new drugs is based on suicidal irreversible inhibitors. Covalent inhibition is the strategy that is used to achieve irreversible inhibition. Irreversible inhibitors interact with their targets in a time-dependent fashion, and the reaction proceeds to completion rather than to equilibrium. Covalent inhibitors possessed some significant advantages over non-covalent inhibitors such as covalent warheads can target rare, non-conserved residue of a particular target protein and thus led to development of highly selective inhibitors, covalent inhibitors can be effective in targeting proteins with shallow binding cleavage which will led to development of novel inhibitors with increased potency than non-covalent inhibitors. Several computational approaches have been developed to simulate covalent interactions; however, this is still a challenging area to explore. Covalent molecular docking has been recently implemented in the computer-aided drug design workflows to describe covalent interactions between inhibitors and biological targets. In this review we highlight: (i) covalent interactions in biomolecular systems; (ii) the mathematical framework of covalent molecular docking; (iii) implementation of covalent docking protocol in drug design workflows; (iv) applications covalent docking: case studies and (v) shortcomings and future perspectives of covalent docking. To the best of our knowledge; this review is the first account that highlights different aspects of covalent docking with its merits and pitfalls. We believe that the method and applications highlighted in this study will help future efforts towards the design of irreversible inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Examples of covalent inhibitors including their protein target(s) with active-site nucleophile: (A) aspirin; (B) neratinib; (C) rivastigmine; (D) Crystal structure of EGFR kinase domain in complex with neratinib, showing the covalent bond between the receptor and the ligand [27].](https://figures.cochat.ai/paper-figures/4c29b35814fb4c5895f870ace31f2ee7/theory-and-applications-of-covalent-docking-in-drug-discovery-merits-and-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Due to the increasing interest in covalent drugs, many non-covalent docking programs have developed covalent versions and some new docking programs focused on covalent ligands have been developed (Kumalo et al., 2015; Awoonor-Williams et al., 2017; De Cesco et al., 2017).”
From Empirical scoring functions for structure-based virtual screening: applications, critical aspects, and challenges (2018) · cites this paper as Kumalo et al., 2015
In the citing paper
“However, the majority of covalent algorithms are limited to accurately calculating the binding energy between a nucleophilic protein and an electrophilic small molecule (Fig. 4) [74].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412 · cited 1×
“The most common docking programs and software include Autodock [31], Autodock Vina [32], GOLD [33] and FlexX [34].”
MethodAutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486 · cited 5×
“The most common docking programs and software include Autodock [31], Autodock Vina [32], GOLD [33] and FlexX [34].”
BackgroundMethodInfluentialFriesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051256o · Cited by 6,851 · cited 1×
“com/web/ Autodock [60] Glide [61] CovDock [62]”
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763 · cited 4×
“Zhang et al., reported covalent docking (using GOLD version 4.0) in conjunction with molecular dynamics (MD) simulation (Amber Molecular Dynamics Package version 8.0) to explore the binding mode of peptide aldehyde inhibitors as anti-tumor drugs (Figure 4C,D).”
MethodInfluentialA Fast Flexible Docking Method using an Incremental Construction Algorithm
Rarey, M., Kramer, B., Lengauer, T., & Klebe, G. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0477 · Cited by 2,827 · cited 2×
“The most common docking programs and software include Autodock [31], Autodock Vina [32], GOLD [33] and FlexX [34].”
BackgroundMethodThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“Examples of covalent inhibitors including their protein target(s) with active-site nucleophile: (A) aspirin; (B) neratinib; (C) rivastigmine; (D) Crystal structure of EGFR kinase domain in complex with neratinib, showing the covalent bond between the receptor and the ligand [27].”
BackgroundThe resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873 · cited 3×
“However, not all drugs bind non-covalently to the active site; there are other categories of drugs, namely the covalent drugs [14].”
BackgroundInfluentialAcetylation of prostaglandin synthase by aspirin.
Roth, G. J., Stanford, N., & Majerus, P. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.3073 · Cited by 1,009 · cited 1×
“The earliest example of a covalent drug is aspirin, which was first marketed over a century ago; aspirin covalently modifies cyclooxygenase by inducing the acetylation of a serine residue that is situated in the active site (Figure 1A) [15–18].”
BackgroundAbagyan, R., & Totrov, M. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1052 · Cited by 975 · cited 1×
“Abagyan and Totrov developed a 4D-docking protocol for Internal Coordinate Mechanics (ICM), where the receptor conformation is the fourth dimension [63–65].”
MethodDrugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839 · cited 1×
“These types of inhibitors derive their activity from both non-covalent interactions and the formation of the covalent bond between the inhibitor and the target protein [8–13].”
Background
Research works printed but not linked: 1
- Ding, 2002, Computational manufacturing, Prog. Nat. Sci., 12, 641
Cited by
Molecular Docking and Structure-Based Drug Design Strategies
Ferreira, L., Dos Santos, R., Oliva, G., & Andricopulo, A. (2015) · Molecules · doi:10.3390/molecules200713384 · Cited by 2,528
“Recent reports have claimed that approximately one-third of the currently marketed enzyme modulators are covalent inhibitors [88].”
BackgroundGuedes, I. A., Pereira, F. S. S., & Dardenne, L. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01089 · Cited by 331
“Due to the increasing interest in covalent drugs, many non-covalent docking programs have developed covalent versions and some new docking programs focused on covalent ligands have been developed (Kumalo et al., 2015; Awoonor-Williams et al., 2017; De Cesco et al., 2017).”
BackgroundMethodCovalent inhibitors design and discovery.
De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.019 · Cited by 315
“The rising interest in covalent drugs has resulted in a surge in the development of docking methods to bolster their discovery and design [108].”
BackgroundDocking Screens for Novel Ligands Conferring New Biology: Miniperspective
Irwin, J. J., & Shoichet, B. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b02008 · Cited by 277
Molecular Docking for Drug Discovery and Development: A Widely Used Approach but Far from Perfect
Wang, G., & Zhu, W. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0143 · Cited by 175
Comparative Evaluation of Covalent Docking Tools
Scarpino, A., Ferenczy, G. G., & Keserű, G. M. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00228 · Cited by 153
Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2
Al-Khafaji, K., AL-Duhaidahawi, D., & Taşkın‐Tok, T. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1764392 · Cited by 153
“The crystal structure of FDA-available covalent drugs which available in Table 1 were selected based on the review of Kumalo et al. (2015) and some of the antiviral drugs that can form a covalent bond to the target protein.”
BackgroundMethodFragment-based covalent ligand discovery
Lu, W., Kostic, M., Zhang, T., Che, J., Patricelli, M. P., Jones, L. H., Chouchani, E. T., & Gray, N. S. (2021) · RSC Chemical Biology · doi:10.1039/d0cb00222d · Cited by 136
Acoplamiento Molecular: Avances Recientes y Retos
Prieto-Martínez, F. D., Arciniega, M., & Medina‐Franco, J. L. (2018) · TIP Revista Especializada en Ciencias Químico-Biológicas · doi:10.22201/fesz.23958723e.2018.0.143 · Cited by 150
10 Years Into the Resurgence of Covalent Drugs
De Vita, E. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0236 · Cited by 122
Recent Advances in Covalent Drug Discovery
Schaefer, D., & Cheng, X. (2023) · Pharmaceuticals · doi:10.3390/ph16050663 · Cited by 122
“Although covalent binders can be toxic due to the undesired modification of off-target proteins or haptenization [8,12], compounds that rely on covalent mechanisms are among the major classes of small molecules, representing about 30% of all active substances on the market.”
BackgroundMacip, G., Garcia‐Segura, P., Mestres‐Truyol, J., Saldivar‐Espinoza, B., Ojeda, M. J., Gimeno, A., Cereto‐Massagué, A., García-Vallvé, S., & Pujadas, G. (2021) · Medicinal Research Reviews · doi:10.1002/med.21862 · Cited by 115
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
Modeling covalent-modifier drugs.
Awoonor-Williams, E., Walsh, A. G., & Rowley, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2017.05.009 · Cited by 90
Synthesis, molecular modeling and anticancer activity of new coumarin containing compounds
Morsy, S. A., Farahat, A. A., Nasr, M. N. A., & Tantawy, A. S. (2017) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2017.02.003 · Cited by 89
“The majority of docking methods development research has been focused on the effective prediction of the binding modes of non-covalent inhibitors (Kumalo et al., 2015).”
Abdelgaleil, S. A. M., Badawy, M. E. I., Mahmoud, N. F., & Marei, A. E. M. (2019) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2019.02.006 · Cited by 91
Aljoundi, A., Bjij, I., El-Rashedy, A. A. E., & Soliman, M. E. S. (2020) · The Protein Journal · doi:10.1007/s10930-020-09884-2 · Cited by 84
Self-citationMolecular Docking: A Structure-Based Approach for Drug Repurposing
Kumar, S., & Kumar, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00006-7 · Cited by 98
Carter-Fenk, K., Lao, K. U., & Herbert, J. M. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00387 · Cited by 75
“56 Given that about 70% of drugs function via non-covalent ligand − protein binding, 57 it is natural to wonder whether e ffi cient but accurate quantum-chemical methods could be used to improve “ knowledge-based ” (but largely physics-free) scoring functions.”
The expanding repertoire of covalent warheads for drug discovery
Mehta, N. V., & Degani, M. S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103799 · Cited by 86
Milenković, D., Avdović, E., Dimić, D., Sudha, S., Ramarajan, D., Milanović, Ž., Trifunović, S. R., & Marković, Z. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.127935 · Cited by 70
Covalent inhibition of protein tyrosine phosphatases
Ruddraraju, K. V., & Zhang, Z. (2017) · Molecular BioSystems · doi:10.1039/c7mb00151g · Cited by 68
Andrade-Ochoa, S., Correa‐Basurto, J., Rodríguez-Valdez, L. M., Sánchez‐Torres, L. E., Nogueda‐Torres, B., & Nevárez‐Moorillón, G. V. (2018) · Chemistry Central Journal · doi:10.1186/s13065-018-0425-2 · Cited by 67
“Docking describe ligand binding to a receptor through noncovalent interactions which is commonly used to explore the ligand recognition on targets for new drug development [20].”
BackgroundDocking of Covalent Ligands: Challenges and Approaches
Sotriffer, C. (2018) · Molecular Informatics · doi:10.1002/minf.201800062 · Cited by 63
The important role of non‐covalent drug‐protein interactions in drug hypersensitivity reactions
Pichler, W. J. (2021) · Allergy · doi:10.1111/all.14962 · Cited by 64
Molecular Docking Studies of HIV-1 Resistance to Reverse Transcriptase Inhibitors: Mini-Review
Tarasova, O. A., Poroikov, V., & Veselovsky, A. V. (2018) · Molecules · doi:10.3390/molecules23051233 · Cited by 55
Xu, C., Ke, Z., Liu, C., Wang, Z., Liu, D., Zhang, L., Wang, J., He, W., Xu, Z., Li, Y., et al. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00821 · Cited by 55
Tessaro, F., & Scapozza, L. (2020) · Molecules · doi:10.3390/molecules25122749 · Cited by 57
Abdelfattah, M. A. O., Dmirieh, M., Bakrim, W. B., Mouhtady, O., Ghareeb, M. A., Wink, M., & Sobeh, M. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115187 · Cited by 55
Ai, Y.-B., Yu, L.-L., Tan, X., Chai, X., & Liu, S. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00334 · Cited by 56
Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery
McAulay, K., Bilsland, A. E., & Bon, M. (2022) · Pharmaceuticals · doi:10.3390/ph15111366 · Cited by 60
New drug design with covalent modifiers
Adeniyi, A. A., Ramesh, M., & Soliman, M. E. S. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1115478 · Cited by 48
Self-citationMolecular Docking of Ferulic Acid Derivatives on P2Y12 Receptor and their ADMET Prediction
Ekowati, J., Diyah, N. W., Nofianti, K. A., Hamid, I. S., & Siswandono, S. (2018) · Journal of Mathematical and Fundamental Sciences · doi:10.5614/j.math.fund.sci.2018.50.2.8 · Cited by 44
“The structural changes of a compound will alter the physicochemical properties of the compound, including its lipophilic, electronic and steric properties, which may cause changes in its biological activity [7,8].”
BackgroundDocking Paradigm in Drug Design
Sulimov, V. B., Kutov, D. C., Taschilova, A. S., Ilin, I. S., Tyrtyshnikov, E. E., & Sulimov, A. V. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666201207095626 · Cited by 45
Advanced approaches of developing targeted covalent drugs
Gai, C., Harnor, S. J., Zhang, S., Cano, C., Zhuang, C., & Zhao, Q. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00216g · Cited by 47
Santucci, M., Spyrakis, F., Cross, S., Quotadamo, A., Farina, D. S. F., Tondi, D., Luca, F. D., Docquier, J., Prieto, A. I., Ibacache‐Quiroga, C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17399-7 · Cited by 50
Covalent binders in drug discovery
Vasudevan, A., Argiriadi, M. A., Baranczak, A., Friedman, M., Gavrilyuk, J. I., Hobson, A. D., Hulce, J. J., Osman, S., & Wilson, N. S. (2019) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2018.12.002 · Cited by 46
Bianco, G., Goodsell, D. S., & Forli, S. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.10.005 · Cited by 44
“Several detailed reviews of methods are available, so individual methods are not compared here [52,63,64].”
MethodSystematic Studies on the Protocol and Criteria for Selecting a Covalent Docking Tool
Wen, C., Yan, X., Gu, Q., Du, J., Wu, D., Lu, Y., Zhou, H., & Xu, J. (2019) · Molecules · doi:10.3390/molecules24112183 · Cited by 40
“The challenges for covalent docking tools have been previously summarized [31,32].”
BackgroundCovBinderInPDB: A Structure-Based Covalent Binder Database
Guo, X.-K., & Zhang, Y. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01216 · Cited by 37
Statistical Analysis and Prediction of Covalent Ligand Targeted Cysteine Residues
Zhang, W., Pei, J., & Lai, L. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00163 · Cited by 38
Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview
Guedes, R. A., Serra, P., Salvador, J. A. R., & Guedes, R. C. (2016) · Molecules · doi:10.3390/molecules21070927 · Cited by 33
Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19
Redhead, M. A., Owen, C. D., Brewitz, L., Collette, A. H., Lukacik, P., Strain-Damerell, C. M., Robinson, S. W., Collins, P. M., Schäfer, P., Swindells, M. B., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92416-4 · Cited by 34
Discovery of highly potent, selective, covalent inhibitors of JAK3
Kempson, J., Ovalle, D., Guo, J., Wrobleski, S. T., Lin, S., Spergel, S. H., Duan, J. J.-W., Jiang, B., Lu, Z., Das, J., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.09.023 · Cited by 32
Wu, Y., & Brooks, C. L. (2022) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-022-00472-3 · Cited by 32
“Targeted covalent inhibitors (TCIs) have gained increased interest in drug discovery in the last two decades, with nearly 30% of currently marketed drugs known to be covalently bound to the therapeutic target [1–3].”
BackgroundIdentification of Covalent Binding Sites Targeting Cysteines Based on Computational Approaches
Zhang, Y., Zhang, D., Tian, H.-Z., Jiao, Y., Shi, Z., Ran, T., Liu, H., Lü, S., Xu, A., Qiao, X., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00302 · Cited by 35
Yalçın, S., Yalçınkaya, S., & Ercan, F. S. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130556 · Cited by 28
Hassab, M. A. E., Farès, M., Amin, M. K. A., Al‐Rashood, S. T., Alharbi, A., Eskandrani, R. O., Alkahtani, H. M., & Eldehna, W. M. (2021) · Processes · doi:10.3390/pr9061004 · Cited by 27
“The alpha ketone group in RMH148 was selected as the reactive warhead group and the residue Cys145 was selected as the reactive site of the receptor [37].”
MethodOpoku, F., Govender, P. P., Pooe, O. J., & Simelane, M. B. C. (2019) · Biomolecules · doi:10.3390/biom9120861 · Cited by 26
“Molecular docking is a theoretical technique which is used to predict the protein–ligand interaction, as well as to characterise the behaviour of the ligands in the binding pocket of the target receptor [12].”
MethodTechnologies for Direct Detection of Covalent Protein–Drug Adducts
Mons, E., Kim, R. Q., & Mulder, M. P. C. (2023) · Pharmaceuticals · doi:10.3390/ph16040547 · Cited by 26
Lefin, N., Belén, L. H., Farías, J. G., & Beltrán, J. F. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10718-3 · Cited by 27
“However, this methodology has limitations, such as low precision of structures and conformational changes during binding [73, 74].”
Use of Molecular Docking as a Decision-Making Tool in Drug Discovery
Abdolmaleki, A., Shiri, F., & Ghasemi, J. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822312-3.00010-2 · Cited by 34
Sasikala, S., Jenifer, M. M., Velavan, K., Sakthivel, M., Sivasamy, R., & Antony, E. R. F. (2023) · Scientific Reports · doi:10.1038/s41598-023-35552-3 · Cited by 22
DUckCov: a Dynamic Undocking‐Based Virtual Screening Protocol for Covalent Binders
Rachman, M. M., Scarpino, A., Bajusz, D., Pálfy, G., Vida, I., Perczel, A., Barril, X., & Keserű, G. M. (2019) · ChemMedChem · doi:10.1002/cmdc.201900078 · Cited by 23
Khan, S., Bjij, I., Olotu, F. A., Agoni, C., Adeniji, E. A., & Soliman, M. E. S. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0304 · Cited by 23
Self-citationBhowmik, R., Kant, R., Manaithiya, A., Saluja, D., Vyas, B., Nath, R., Qureshi, K. A., Parkkila, S., & Aspatwar, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1265573 · Cited by 19
Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
de Araújo, R. S. A., da Silva‐Júnior, E. F., de Aquino, T. M., Scotti, L., Ishiki, H. M., Scotti, L., & Mendonça, F. J. B. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200607191838 · Cited by 20
Shaheen, N., Qureshi, N. A., Ashraf, A., Hamid, A., Iqbal, A., & Fatima, H. (2020) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2020.112077 · Cited by 18
Inhibition of metabolic cooperation in Chinese hamster cells by organochlorine pesticides.
Kurata, M., Hirose, K., & Umeda, M. (1982) · PubMed · Cited by 22
Soulère, L., Barbier, T., & Queneau, Y. (2021) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2021.107463 · Cited by 19
“, 2004), docking studies for covalent protein inhibition are less common (Kumalo et al., 2015; Sotriffer, 2018), in particular with SARS-CoV-2 main protease (Liu et al.”
Integrated Covalent Drug Design Workflow Using Site Identification by Ligand Competitive Saturation
Yu, W., Weber, D. J., & MacKerell, A. D. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00232 · Cited by 16
“Like noncovalent drug design, computer-aided drug design (CADD) approaches (11) have become an”
Hasan, M. N., Ray, M., & Saha, A. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c04710 · Cited by 17
Olotu, F. A., Adeniji, E. A., Agoni, C., Bjij, I., Khan, S., El-Rashedy, A. A. E., & Soliman, M. E. S. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1516035 · Cited by 17
Self-citationModeling of ribonucleic acid–ligand interactions
Stefaniak, F., Chudyk, E. I., Bodkin, M. J., Dawson, W., & Bujnicki, J. M. (2015) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1226 · Cited by 20
“99 An example could be DOCKova-lent, a modified version of the DOCK 3.6 program, aiming at covalent docking of large libraries of compounds.”
MethodInfluentialTargeted degrader technologies as prospective SARS-CoV-2 therapies
Khurshid, R., Schulz, J. M., Hu, J., Snowden, T. S., Reynolds, R. C., & Schürer, S. C. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103847 · Cited by 14
Javed, S., Mahipal, B., Torres, J., Ganguly, A., & Hanson, P. R. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201601004 · Cited by 15
Niraj, R. R. K., Saini, V., & Kumar, A. (2015) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2015.09.021 · Cited by 15
Panday, S. K., & Ghosh, I. (2019) · Challenges and advances in computational chemistry and physics · doi:10.1007/978-3-030-05282-9_5 · Cited by 18
Hamri, S., Bouchaour, T., Lerari, D., Bouberka, Z., Supiot, P., & Maschke, U. (2022) · Gels · doi:10.3390/gels8030156 · Cited by 13
Azam, F., & Almahmoud, S. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073302 · Cited by 14
The Comparison of Docking Search Algorithms and Scoring Functions: An Overview and Case Studies
Novič, M., Tibaut, T., Anderluh, M., Borišek, J., & Tomašič, T. (2016) · Advances in medical technologies and clinical practice book series · doi:10.4018/978-1-5225-0115-2.ch004 · Cited by 17
Kim, H., Jo, A., Choi, S., Nam, H., Byun, W. G., Bae, H., Choi, J. H., & Park, S. B. (2018) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.201800668 · Cited by 14
Zsidó, B. Z., Börzsei, R., Pintér, E., & Hetényi, C. (2021) · Pharmaceuticals · doi:10.3390/ph14100988 · Cited by 14
“The formation of the covalent bond between the agonist and TRPA1 (Figure 3) is a quantum mechanical phenomenon, which is hard to treat adequately by docking programs based on molecular mechanics scoring functions [23,24].”
BackgroundYao, Z., Zhang, L., Gao, B., Cui, D., Wang, F., He, X. D., Zhang, J. Z. H., & Wei, D. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00585 · Cited by 11
Virtual screening using covalent docking to find activators for G245S mutant p53
Omar, S. I., Lepre, M. G., Morbiducci, U., Deriu, M. A., & Tuszyński, J. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200769 · Cited by 10
QSAR of clinically important EGFR mutant L858R/T790M pyridinylimidazole inhibitors
Fatima, S., Pal, D., & Agarwal, S. M. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13505 · Cited by 10
“…that they have some additional advantages like high selectivity, can overcome high endogenous ATP concentration, high residence time as well as can prevent emergence of acquired resistance due to mutations (Garuti, Roberti, & Bottegoni, 2011; Kumalo et al., 2015; Smith, Zhang, Leach, & Houk, 2009).”
BackgroundComputational Methods Used in Phytocompound-Based Drug Discovery
Rallabandi, H. R., Mekapogu, M., Natesan, K., Saindane, M., Dhupal, M., Swamy, M. K., & Vasamsetti, B. M. K. (2020) · Springer eBooks · doi:10.1007/978-981-15-2361-8_25 · Cited by 14
The covalent docking software landscape: features and applications in drug design
Singh, N., Vayer, P., & Villoutreix, B. O. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf697 · Cited by 10
“While SBVS is usually efficient for noncovalent hits, the approach is not without pitfalls [35–40].”
Sahre, M. J., von Rudorff, G. F., & von Lilienfeld, O. A. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c13393 · Cited by 9
Phelix, C. F., Bourdon, A. K., Dugan, J. L., Villareal, G., & Perry, G. L. (2017) · International Journal of Knowledge Discovery in Bioinformatics · doi:10.4018/ijkdb.2017070103 · Cited by 9
Schumann, P. G., Chang, D. T., Mayasich, S. A., Vliet, S. M. F., Brown, T. N., & LaLone, C. A. (2024) · Computational Toxicology · doi:10.1016/j.comtox.2024.100319 · Cited by 8
Jisha Pillai, U., Singh, P., Maan, M., Jayakumar, M. N., Donakonda, S., Iype, E., & Dutta, M. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118340 · Cited by 7
UBE2N: Hope on the Cancer Front, How to Inhibit This Promising Target Prospect?
Schwalen, F., Ghadi, C., Ibazizene, L., Khan, S. U., Santos, J. S. O., Weiswald, L., Voisin‐Chiret, A. S., Meryet‐Figuière, M., & Kieffer, C. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01517 · Cited by 8
Bansode, T. S., & Salalkar, B. K. (2016) · Preprints.org · doi:10.20944/preprints201609.0073.v1 · Cited by 7
Integration of molecular modelling and in vitro studies to inhibit LexA proteolysis
Schuurs, Z. P., McDonald, J. P., Croft, L. V., Richard, D. J., Woodgate, R., & Gandhi, N. S. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1051602 · Cited by 6
“This was used as Maestro Suite is considered to have one of the best high-throughput covalent docking implementations (Kumalo et al., 2015; Scarpino et al., 2018).”
BackgroundMethodSalah, T., Belaıdı, S., Melkemi, N., Daoud, I., & Boughdiri, S. (2016) · Journal of Theoretical and Computational Chemistry · doi:10.1142/s0219633616500218 · Cited by 6
Malla, S., Kadimisetty, K., Fu, Y., Choudhary, D., Schenkman, J. B., & Rusling, J. F. (2017) · Scientific Reports · doi:10.1038/srep40890 · Cited by 6
Platinum complexes as inhibitors of DNA repair protein Ku70 and topoisomerase IIα in cancer cells
Zhang, H., Wang, Y., Wang, Y., Han, Q., Yan, H., Yang, T., Guo, Z., & Wang, X. (2022) · Dalton Transactions · doi:10.1039/d1dt03700e · Cited by 6
Characterization of caspase‐2 inhibitors based on specific sites of caspase‐2‐mediated proteolysis
Bresinsky, M., Strasser, J. M., Hubmann, A., Vallaster, B., McCue, W. M., Fuller, J. L., Singh, G., Nelson, K. M., Cuellar, M. E., Finzel, B. C., et al. (2022) · Archiv der Pharmazie · doi:10.1002/ardp.202200095 · Cited by 9
From covalent bonds to eco-physiological pharmacology of secondary plant metabolites
Chatterjee, S. S. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.037 · Cited by 7
Zhang, S., He, Y., & Wei, M. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.106105 · Cited by 5
Computational investigation of turmeric phytochemicals targeting PTR1 enzyme of Leishmania species
Ullah, W., Wu, W., Malak, N., Nasreen, N., Swelum, A. A., Aguilar-Marcelino, L., Niaz, S., Khan, A. N., Saïd, M. B., & Chen, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27907 · Cited by 5
“Incorporating covalent molecule docking into computer-aided drug design strategies allows for the characterization of covalent bonds between biological targets and inhibitors, enriching our understanding of interactions [49].”
BackgroundRoad Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors
Shunmugam, L., Ramharack, P., & Soliman, M. E. S. (2017) · The Protein Journal · doi:10.1007/s10930-017-9736-8 · Cited by 6
Self-citationMahdizadeh, S. J., Carlesso, A., & Eriksson, L. A. (2020) · RSC Advances · doi:10.1039/d0ra01895c · Cited by 5
Venetoclax: a promising repurposed drug against SARS-CoV-2 main protease
Ghosh, S., Bhattacherjee, D., Satpati, P., & Bhabak, K. P. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1967786 · Cited by 6
“The objective of docking was to rank non-covalent organosulfur binders for Mpro, rather the complicated covalent docking in the workflow, which is certainly limited by accuracy, speed, sampling and protein flexibility (Kumalo et al., 2015).”
BackgroundAllam, S., Abo-Shnaf, R. I. A., El-Hawary, A. A., El-Shaer, A. A., Shalaby, A. A., El-Sobky, M. L., & Abdul-Shafy, A. F. (2023) · International Journal of Acarology · doi:10.1080/01647954.2023.2281534 · Cited by 5
“These types of connections with objective receptors are found in active biological compounds such as enzyme inhibitors (Davis and Teague 1999; Kumalo et al. 2015).”
BackgroundDiscovery of novel covalent stabilizers for p53 Y220C using structure-based drug discovery methods
Wen, Y., Xu, P., Chen, Y., Meng, J., Zheng, M., Zhang, S., Teng, D., & Li, X. (2025) · Molecular Diversity · doi:10.1007/s11030-024-11095-1 · Cited by 4
Georgieva, S. F., Cherneva, D. P., Mihalev, K., Iliev, I., Agova, N. V., Yaneva, G. A., & Димитрова, Ц. (2025) · Applied Sciences · doi:10.3390/app15137536 · Cited by 4
Chandrasekaran, B., Al-Joubi, H., Samarneh, S., Kassab, G. H., Deb, P. K., Kumar, P., Al-Jaidi, B. A., Thaher, Y. A., & Bataineh, Y. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-3556-7_2 · Cited by 4
Biomolecular Talks—Part 1: A Theoretical Revisit on Molecular Modeling and Docking Approaches
Ramaswamy, A., Balasubramanian, S., & Rajagopalan, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822312-3.00015-1 · Cited by 5
Metadata
- Authors
- Kumalo, H., Bhakat, S., & Soliman, M.
- Affiliations
- University of KwaZulu-Natal (ZA)
- Corresponding author
- Soliman, Mahmoud
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2015-01-27
- Volume
- 20
- Issue
- 2
- Pages
- 1984-2000
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC6272664
- OpenAlex
- W2029963983
- Cited by
- 158
- References
- 68
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 10 · 2023: 17 · 2022: 11 · 2021: 17 · 2020: 17 · 2019: 11 · 2018: 13 · 2017: 13 · 2016: 19 · 2015: 5
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation
- Inyuvesi Yakwazulu-Natali
- Center for High Performance Computing
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- covalent docking, covalent inhibitors, irreversible inhibition, computer-aided drug design, covalent interactions, protein-ligand binding, covalent warheads, selective inhibitors
- MeSH terms
- Humans, Protein Binding, Software, Thermodynamics, Drug Discovery, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.